Genesis IBRC India (GENESIS) | Financial Analysis & Statements
Genesis IBRC India Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
0
Operating Income
-1.2M
Net Income
-1.2M
EPS (Diluted)
₹-0.09
Balance Sheet Metrics
Total Assets
88.4M
Total Liabilities
3.0M
Shareholders Equity
85.3M
Debt to Equity
0.04
Cash Flow Metrics
Revenue & Profitability Trend
Genesis IBRC India Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 152.0K | 172.0K | 101.0K | 73.0K | 115.0K |
| Other Operating Expenses | -35.7M | 37.4M | 696.0K | 670.0K | 627.0K |
| Total Operating Expenses | -35.6M | 37.6M | 797.0K | 743.0K | 742.0K |
| Operating Income | 35.0M | -38.0M | -940.0K | -1.2M | -1.2M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 0 | 3.0K | 0 | 4.0K | 0 |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 35.0M | -38.0M | -1.4M | -1.2M | -1.2M |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | 35.0M | -38.0M | -1.4M | -1.2M | -1.2M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | 35.0M | -38.0M | -940.0K | -1.2M | -1.2M |
| EPS (Basic) | ₹2.70 | ₹-2.92 | ₹-0.11 | ₹-0.09 | ₹-0.09 |
| EPS (Diluted) | ₹2.70 | ₹-2.92 | ₹-0.11 | ₹-0.09 | ₹-0.09 |
| Basic Shares Outstanding | 13000000 | 13000000 | 13000000 | 13000000 | 13000000 |
| Diluted Shares Outstanding | 13000000 | 13000000 | 13000000 | 13000000 | 13000000 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Genesis IBRC India Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 57.0K | 60.0K | 71.0K | 138.0K | 89.0K |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 0 | 0 | 0 | 434.0K | 434.0K |
| Inventory | - | - | - | - | - |
| Other Current Assets | 51.6M | 52.0M | -1.0K | 45.9M | -1 |
| Total Current Assets | 88.4M | 52.1M | 89.7M | 90.9M | 92.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | - | - | - | - | - |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | - | - | - |
| Total Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 88.4M | 52.1M | 89.7M | 90.9M | 92.0M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 374.0K | 377.0K | 377.0K | 377.0K | 377.0K |
| Short-term Debt | - | - | - | - | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.9M | 1.3M | 990.0K | 938.0K | 751.0K |
| Total Current Liabilities | 3.0M | 1.8M | 1.4M | 1.3M | 1.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | - | - | - | - | - |
| Deferred Tax Liabilities | - | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | - | - | -1.0K | - | - |
| Total Non-Current Liabilities | 0 | 0 | -1.0K | 0 | 0 |
| Total Liabilities | 3.0M | 1.8M | 1.4M | 1.3M | 1.2M |
| Equity | |||||
| Common Stock | 130.0M | 130.0M | 130.0M | 130.0M | 130.0M |
| Retained Earnings | -83.1M | -118.1M | -80.1M | -78.8M | -77.6M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 85.3M | 50.3M | 88.3M | 89.6M | 90.8M |
| Key Metrics | |||||
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Working Capital | 85.3M | 50.3M | 88.3M | 89.6M | 90.8M |
Balance Sheet Composition
Genesis IBRC India Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 35.0M | -38.0M | -1.4M | -1.2M | -1.2M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -35.0M | 31.5M | 454.0K | -10.0K | -46.0K |
| Operating Cash Flow | 0 | -6.5M | -920.0K | -1.2M | -1.2M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | 0 | 0 | 0 | 0 |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | - | 0 | 0 | 0 | 0 |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 0 | - | - | - | - |
| Free Cash Flow | -3.0K | -11.0K | -920.0K | -1.2M | -1.2M |
| Net Change in Cash | 0 | -6.5M | -920.0K | -1.2M | -1.2M |
Cash Flow Trend
Genesis IBRC India Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
57.89
Price to Book
9.93
Price to Sales
1,399.83
Profitability Ratios
Profit Margin
2.36%
Operating Margin
-11.05%
Return on Equity
0.08%
Return on Assets
0.05%
Financial Health
Current Ratio
21.60
Debt to Equity
0.00
Per Share Data
EPS (TTM)
₹-0.18
Book Value per Share
₹9.02
Revenue per Share
₹0.28
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| GENESIS | 4.5B | 57.89 | 9.93 | 0.08% | 2.36% | 0.00 |
| Biocon | 566.5B | 71.84 | 1.68 | 3.66% | 3.59% | 50.02 |
| OneSource Specialty | 202.8B | 936.63 | 3.11 | -0.31% | 1.42% | 21.93 |
| Zota Health Care | 39.4B | -62.53 | 12.61 | -24.83% | -15.37% | 56.90 |
| Dishman Carbogen | 26.5B | 22.30 | 0.42 | 0.06% | 4.25% | 40.20 |
| Panacea Biotec | 21.8B | 182.62 | 2.65 | -1.01% | -1.29% | 2.79 |
Financial data is updated regularly. All figures are in the company's reporting currency.




